Article Text

Download PDFPDF

BTS guideline for the investigation and management of malignant pleural mesothelioma
  1. Ian Woolhouse1,
  2. Lesley Bishop2,
  3. Liz Darlison3,
  4. Duneesha de Fonseka4,
  5. Anthony Edey5,
  6. John Edwards6,
  7. Corinne Faivre-Finn7,
  8. Dean A Fennell8,
  9. Steve Holmes9,
  10. Keith M Kerr10,
  11. Apostolos Nakas11,
  12. Tim Peel12,
  13. Najib M Rahman13,
  14. Mark Slade14,
  15. Jeremy Steele15,
  16. Selina Tsim16 and
  17. Nick A Maskell17
  1. 1 Department of Respiratory Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
  2. 2 Respiratory, Queen Alexandra Hospital, Portsmouth, UK
  3. 3 Respiratory, University Hospitals of Leicester, Leicester, UK
  4. 4 Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK
  5. 5 North Bristol NHS Trust, Bristol, UK
  6. 6 Sheffield Teaching Hospitals, Sheffield, UK
  7. 7 Division of Cancer Sciences, University of Manchester, Manchester, UK
  8. 8 University of Leicester and University Hospitals of Leicester, Leicester, UK
  9. 9 The Park Medical Practice, Shepton Mallet, UK
  10. 10 University of Aberdeen, Pathology, Aberdeen, UK
  11. 11 Department of Thoracic Surgery, Genfield Hospital, Leicester, UK
  12. 12 North Tyneside General Hospital, North Shields, UK (now retired)
  13. 13 Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK
  14. 14 Papworth Hospital, Thoracic Oncology, Cambridge, UK
  15. 15 Cancer, St Bartholomew’s Hospital, London, UK
  16. 16 Respiratory Medicine, Queen Elizabeth University Hospital, Glasgow, UK
  17. 17 Academic Respiratory Unit, Bristol Medical School, University of Bristol, Bristol, UK
  1. Correspondence to Professor Nick A Maskell; nick.maskell{at}


The full guideline for the investigation and management of malignant pleural mesothelioma is published in Thorax. The following is a summary of the recommendations and good practice points. The sections referred to in the summary refer to the full guideline.

  • mesothelioma

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

View Full Text

Statistics from


  • Contributors IW and NM were the lead authors with overall responsibility for the full guideline. All named authors contributed to drafting the full guideline on which this summary is based and approved the guideline for submission.

  • Competing interests LD has received funding from Irwin Mitchell and Lilly Oncology. DdF has received funding from Roche, MSD, Lilly, BI, BMS, Bayer and Astex. SH has received funding from GSK, Chiesi, Astra Zeneca, MediConf, Pfizer, Sandoz and Napp. KK has received funding from AZ, BI, BMS, Lilly, Merck, MSD, Novartis, Pfizer and Roche. NM has received funding from BD. NR has received funding from Rocket Medical.

  • Provenance and peer review Commissioned; internally peer reviewed.

  • Data sharing statement No additional data are available.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.